Repros Therapeutics Inc  

(Public, NASDAQ:RPRX)   Watch this stock  
Find more results for RPRX
7.41
0.00 (0.00%)
Sep 2 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week 5.91 - 22.42
Open     -
Vol / Avg. 1,200.00/295,475.00
Mkt cap 179.92M
P/E     -
Div/yield     -
EPS -1.31
Shares 24.28M
Beta 0.90
Inst. own 61%
Nov 9, 2015
Q3 2015 Repros Therapeutics Inc Earnings Release (Estimated) Add to calendar
Aug 10, 2015
Q2 2015 Repros Therapeutics Inc Earnings Release
Jun 16, 2015
Repros Therapeutics Inc Annual Shareholders Meeting (Estimated)
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '15) 2014
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -87.94% -52.90%
Return on average equity -94.33% -55.84%
Employees 26 -
CDP Score - -

Address

2408 Timberloch Pl Ste B7
THE WOODLANDS, TX 77380-1021
United States - Map
+1-281-7193400 (Phone)
+1-281-7193446 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Repros Therapeutics, Inc. is a biopharmaceutical company focused on the development of new drugs to treat hormonal and reproductive system disorders. The Company's product candidates include Androxal and Proellex. The Company's primary product candidate Androxal is a single isomer of clomiphene citrate and an orally active proprietary small molecule compound, which is developed for the treatment of secondary hypogonadism in overweight men. The Company's Proellex product candidate for female reproductive health is a chemical entity that acts as a selective blocker of the progesterone receptor and is being developed for the treatment of symptoms associated with uterine fibroids and endometriosis.

Officers and directors

Nola E. Masterson Independent Chairman of the Board
Age: 68
Bio & Compensation  - Reuters
Joseph S. Podolski President, Chief Executive Officer, Director
Age: 67
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Katherine A. Anderson CPA Chief Financial Officer, Chief Accounting Officer, Secretary
Age: 57
Bio & Compensation  - Reuters
Jaye Thompson Ph.D. Senior Vice President - Clinical and Regulatory
Age: 49
Bio & Compensation  - Reuters
Ronald D. Wiehle Ph.D. Vice President - Research & Development
Age: 66
Bio & Compensation  - Reuters
Joachim F. Wernicke Chief Medical Officer
Age: 67
Bio & Compensation  - Reuters
Daniel F. Cain Independent Director
Age: 69
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Saira Ramasastry Independent Director
Age: 39
Bio & Compensation  - Reuters
Michael Suesserman Independent Director
Age: 50
Bio & Compensation  - Reuters
Michael G. Wyllie Ph.D. Independent Director
Age: 64
Bio & Compensation  - Reuters